Agenus Inc (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies, announced yesterday that it has named Dr Allison Jeynes-Ellis as its new director.
Jeynes-Ellis, MD, FFPM (UK) is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Presently, she serves as chief executive officer at Avillion LLP.
Previously, she led development at Wyeth, BMS, Novartis, and GSK and has secured numerous US and EU drug approvals.
Garo Armen, PhD, chairman and CEO of Agenus, said, 'As we advance towards becoming a commercial organisation, I am delighted to welcome Dr Jeynes-Ellis to our board. Allison brings significant global drug development and commercialisation experience, which includes executing on global registrational studies resulting in regulatory approvals in US and EU and advising on commercialisation and reimbursement strategies. We will benefit from Allison's considerable development, regulatory, and commercial expertise.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886